OBJECTIVE	We therefore explored the association between adjuvant tamoxifen treatment in breast cancer and expression of VEGF-A and VEGFR2 , as well as human epidermal growth factor receptor 2 ( HER2 ) , which represents a candidate gene product involved in tamoxifen resistance .\